GUD — Knight Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$608.26m
- CA$486.28m
- CA$328.20m
- 85
- 76
- 87
- 96
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 47.5 | 200 | 243 | 294 | 328 |
Cost of Revenue | |||||
Gross Profit | 26.9 | 81.7 | 115 | 138 | 153 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 64.5 | 232 | 256 | 332 | 328 |
Operating Profit | -17.1 | -32.1 | -12.4 | -38.8 | 0.413 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 22.8 | 32.1 | 6.69 | -44 | -22 |
Provision for Income Taxes | |||||
Net Income After Taxes | 18 | 31.8 | 15.7 | -29.9 | -16.8 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 14.5 | 42.1 | 15.7 | -29.9 | -16.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 14.5 | 42.1 | 15.7 | -29.9 | -16.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.197 | 0.403 | 0.135 | -0.135 | -0.121 |